View in EDS

Feasibility, Safety and Efficacy of Maraviroc, a CCR5 Antagonist, in Graft-Versus-Host Disease Prevention After Reduced intensity Conditioned (RIC) Allogeneic Stem Cell Transplant (SCT): a Phase I/II Study

Saved in:
Bibliographic Details
Title: Feasibility, Safety and Efficacy of Maraviroc, a CCR5 Antagonist, in Graft-Versus-Host Disease Prevention After Reduced intensity Conditioned (RIC) Allogeneic Stem Cell Transplant (SCT): a Phase I/II Study
Authors: Reshef, R.1, Luger, S.M.1, Loren, A.W.1, Frey, N.V.1, Goldstein, S.C.1, Hexner, E.O.1, Stadtmauer, E.A.1, Smith, J.1, Mick, R.1, Heitjan, D.F.1, Hoxie, J.A.1, Emerson, S.G.1, Vonderheide, R.H.1, Porter, D.L.1
Source: Biology of Blood & Marrow Transplantation. Feb2011 Supplement, Vol. 17 Issue 2, pS331-S331. 1p.
Database: Academic Search Ultimate
Description
ISSN:10838791
DOI:10.1016/j.bbmt.2010.12.532